6 O
ADVERSE O
REACTIONS O
The O
following O
are O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Increased O
mortality O
in O
elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Cerebrovascular B-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
, O
including O
stroke B-NonOSE_AE
, O
in O
elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Neuroleptic B-OSE_Labeled_AE
malignant I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Metabolic B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
( O
Hyperglycemia B-OSE_Labeled_AE
and O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
Dyslipidemia B-OSE_Labeled_AE
, O
and O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Hyperprolactinemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Falls B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
agranulocytosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Potential O
for O
cognitive B-OSE_Labeled_AE
and O
motor O
impairment I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Dysphagia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
* O
Priapism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
* O
Disruption B-OSE_Labeled_AE
of I-OSE_Labeled_AE
body I-OSE_Labeled_AE
temperature I-OSE_Labeled_AE
regulation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.14 O
) O
] O
* O
Patients O
with O
Phenylketonuria B-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
. O

The O
most O
common O
adverse O
reactions O
in O
clinical O
trials O
( O
> O
5 O
% O
and O
twice O
placebo O
) O
were O
parkinsonism B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
stomach B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
salivary B-OSE_Labeled_AE
hypersecretion I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
and O
pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

The O
most O
common O
adverse O
reactions O
that O
were O
associated O
with O
discontinuation O
from O
clinical O
trials O
( O
causing O
discontinuation O
in O
> O
1 O
% O
of O
adults O
and/or O
> O
2 O
% O
of O
pediatrics O
) O
were O
nausea B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
and O
akathisia B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
, O
Discontinuations O
Due O
to O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
data O
described O
in O
this O
section O
are O
derived O
from O
a O
clinical O
trial O
database O
consisting O
of O
9803 O
adult O
and O
pediatric O
patients O
exposed O
to O
one O
or O
more O
doses O
of O
RISPERDAL O
( O
r O
) O
for O
the O
treatment O
of O
schizophrenia B-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
, O
autistic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
in O
pediatrics O
and O
elderly B-Not_AE_Candidate
patients O
with O
dementia I-Not_AE_Candidate
. O

Of O
these O
9803 O
patients O
, O
2687 O
were O
patients O
who O
received O
RISPERDAL O
( O
r O
) O
while O
participating O
in O
double-blind O
, O
placebo-controlled O
trials O
. O

The O
conditions O
and O
duration O
of O
treatment O
with O
RISPERDAL O
( O
r O
) O
varied O
greatly O
and O
included O
( O
in O
overlapping O
categories O
) O
double-blind O
, O
fixed- O
and O
flexible-dose O
, O
placebo- O
or O
active-controlled O
studies O
and O
open-label O
phases O
of O
studies O
, O
inpatients O
and O
outpatients O
, O
and O
short-term O
( O
up O
to O
12 O
weeks O
) O
and O
longer-term O
( O
up O
to O
3 O
years O
) O
exposures O
. O

Safety O
was O
assessed O
by O
collecting O
adverse O
events O
and O
performing O
physical O
examinations O
, O
vital O
signs O
, O
body O
weights O
, O
laboratory O
analyses O
, O
and O
ECGs O
. O

EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
in O
clinical O
trials O
( O
> O
=5 O
% O
and O
twice O
placebo O
) O
were O
parkinsonism O
, O
akathisia O
, O
dystonia O
, O
tremor O
, O
sedation O
, O
dizziness O
, O
anxiety O
, O
blurred O
vision O
, O
nausea O
, O
vomiting O
, O
upper O
abdominal O
pain O
, O
stomach O
discomfort O
, O
dyspepsia O
, O
diarrhea O
, O
salivary O
hypersecretion O
, O
constipation O
, O
dry O
mouth O
, O
increased O
appetite O
, O
increased O
weight O
, O
fatigue O
, O
rash O
, O
nasal O
congestion O
, O
upper O
respiratory O
tract O
infection O
, O
nasopharyngitis O
, O
and O
pharyngolaryngeal O
pain O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Janssen O
Pharmaceuticals O
, O
Inc O
. O
at O
1-800-JANSSEN O
( O
1-800-526-7736 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

Commonly-Observed O
Adverse O
Reactions O
in O
Double-Blind O
, O
Placebo-Controlled O
Clinical O
Trials O
- O
Schizophrenia O
Adult O
Patients O
with O
Schizophrenia O
Table O
8 O
lists O
the O
adverse O
reactions O
reported O
in O
2 O
% O
or O
more O
of O
RISPERDAL O
( O
r O
) O
-treated O
adult O
patients O
with O
schizophrenia B-Not_AE_Candidate
in O
three O
4- O
to O
8-week O
, O
double-blind O
, O
placebo-controlled O
trials O
. O

Table O
8 O
. O

Adverse O
Reactions O
in O
> O
=2 O
% O
of O
RISPERDAL O
( O
r O
) O
-Treated O
Adult O
Patients O
( O
and O
greater O
than O
placebo O
) O
with O
Schizophrenia O
in O
Double-Blind O
, O
Placebo-Controlled O
Trials O
Percentage O
of O
Patients O
Reporting O
Reaction O
RISPERDAL O
( O
r O
) O
System/Organ O
Class O
Adverse O
Reaction O
2-8 O
mg O
per O
day O
( O
N=366 O
) O
> O
8-16 O
mg O
per O
day O
( O
N=198 O
) O
Placebo O
( O
N=225 O
) O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Tachycardia B-OSE_Labeled_AE
1 O
3 O
0 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
3 O
1 O
1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
9 O
4 O
4 O
Constipation B-OSE_Labeled_AE
8 O
9 O
6 O
Dyspepsia B-OSE_Labeled_AE
8 O
6 O
5 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
4 O
0 O
1 O
Abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
3 O
1 O
1 O
Salivary B-OSE_Labeled_AE
hypersecretion I-OSE_Labeled_AE
2 O
1 O
< O
1 O
Diarrhea B-OSE_Labeled_AE
2 O
1 O
1 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
3 O
1 O
0 O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
2 O
2 O
1 O
Asthenia B-OSE_Labeled_AE
2 O
1 O
< O
1 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
3 O
4 O
3 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
2 O
3 O
1 O
Sinusitis B-OSE_Labeled_AE
1 O
2 O
1 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
1 O
3 O
0 O
Investigations B-NonOSE_AE
Blood B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
1 O
2 O
< O
1 O
Heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
< O
1 O
2 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
4 O
1 O
1 O
Arthralgia B-OSE_Labeled_AE
2 O
3 O
< O
1 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
2 O
1 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Parkinsonism B-OSE_Labeled_AE
[ O
note O
: O
Parkinsonism B-OSE_Labeled_AE
includes O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
akinesia B-OSE_Labeled_AE
, O
bradykinesia B-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
masked B-OSE_Labeled_AE
facies I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
and O
Parkinson B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

Akathisia B-OSE_Labeled_AE
includes O
akathisia B-OSE_Labeled_AE
and O
restlessness B-OSE_Labeled_AE
. O

Dystonia B-OSE_Labeled_AE
includes O
dystonia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
contractions I-OSE_Labeled_AE
involuntary I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
contracture I-OSE_Labeled_AE
, O
oculogyration B-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
paralysis I-OSE_Labeled_AE
. O

Tremor B-OSE_Labeled_AE
includes O
tremor B-OSE_Labeled_AE
and O
parkinsonian B-OSE_Labeled_AE
rest I-OSE_Labeled_AE
tremor I-OSE_Labeled_AE
. O
] O

14 O
17 O
8 O
Akathisia B-OSE_Labeled_AE
10 O
10 O
3 O
Sedation B-OSE_Labeled_AE
10 O
5 O
2 O
Dizziness B-OSE_Labeled_AE
7 O
4 O
2 O
Dystonia B-OSE_Labeled_AE
3 O
4 O
2 O
Tremor B-OSE_Labeled_AE
2 O
3 O
1 O
Dizziness B-OSE_Labeled_AE
postural I-OSE_Labeled_AE
2 O
0 O
0 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
32 O
25 O
27 O
Anxiety B-OSE_Labeled_AE
16 O
11 O
11 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
4 O
6 O
2 O
Dyspnea B-OSE_Labeled_AE
1 O
2 O
0 O
Epistaxis B-OSE_Labeled_AE
< O
1 O
2 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
1 O
4 O
1 O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
1 O
3 O
0 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
2 O
1 O
0 O
Pediatric O
Patients O
with O
Schizophrenia O
Table O
9 O
lists O
the O
adverse O
reactions O
reported O
in O
5 O
% O
or O
more O
of O
RISPERDAL O
( O
r O
) O
-treated O
pediatric O
patients O
with O
schizophrenia B-Not_AE_Candidate
in O
a O
6-week O
double-blind O
, O
placebo-controlled O
trial O
. O

Table O
9 O
. O

Adverse O
Reactions O
in O
> O
=5 O
% O
of O
RISPERDAL O
( O
r O
) O
-Treated O
Pediatric O
Patients O
( O
and O
greater O
than O
placebo O
) O
with O
Schizophrenia O
in O
a O
Double-Blind O
Trial O
Percentage O
of O
Patients O
Reporting O
Reaction O
RISPERDAL O
( O
r O
) O
System/Organ O
Class O
Adverse O
Reaction O
1-3 O
mg O
per O
day O
( O
N=55 O
) O
4-6 O
mg O
per O
day O
( O
N=51 O
) O
Placebo O
( O
N=54 O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Salivary B-OSE_Labeled_AE
hypersecretion I-OSE_Labeled_AE
0 O
10 O
2 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Sedation B-OSE_Labeled_AE
24 O
12 O
4 O
Parkinsonism B-OSE_Labeled_AE
[ O
note O
: O
Parkinsonism B-OSE_Labeled_AE
includes O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
and O
hypokinesia B-OSE_Labeled_AE
. O

Akathisia B-OSE_Labeled_AE
includes O
akathisia B-OSE_Labeled_AE
and O
restlessness B-OSE_Labeled_AE
. O

Dystonia B-OSE_Labeled_AE
includes O
dystonia B-OSE_Labeled_AE
and O
oculogyration B-OSE_Labeled_AE
. O
] O

16 O
28 O
11 O
Tremor B-OSE_Labeled_AE
11 O
10 O
6 O
Akathisia B-OSE_Labeled_AE
9 O
10 O
4 O
Dizziness B-OSE_Labeled_AE
7 O
14 O
2 O
Dystonia B-OSE_Labeled_AE
2 O
6 O
0 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
7 O
6 O
0 O
Commonly-Observed O
Adverse O
Reactions O
in O
Double-Blind O
, O
Placebo-Controlled O
Clinical O
Trials O
- O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
Adult O
Patients O
with O
Bipolar O
Mania O
Table O
10 O
lists O
the O
adverse O
reactions O
reported O
in O
2 O
% O
or O
more O
of O
RISPERDAL O
( O
r O
) O
-treated O
adult O
patients O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
in O
four O
3-week O
, O
double-blind O
, O
placebo-controlled O
monotherapy O
trials O
. O

Table O
10 O
. O

Adverse O
Reactions O
in O
> O
=2 O
% O
of O
RISPERDAL O
( O
r O
) O
-Treated O
Adult O
Patients O
( O
and O
greater O
than O
placebo O
) O
with O
Bipolar O
Mania O
in O
Double-Blind O
, O
Placebo-Controlled O
Monotherapy O
Trials O
Percentage O
of O
Patients O
Reporting O
Reaction O
System/Organ O
Class O
Adverse O
Reaction O
RISPERDAL O
( O
r O
) O
1-6 O
mg O
per O
day O
( O
N=448 O
) O
Placebo O
( O
N=424 O
) O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
2 O
1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
5 O
2 O
Diarrhea B-OSE_Labeled_AE
3 O
2 O
Salivary B-OSE_Labeled_AE
hypersecretion I-OSE_Labeled_AE
3 O
1 O
Stomach B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
2 O
< O
1 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
2 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Parkinsonism B-OSE_Labeled_AE
[ O
note O
: O
Parkinsonism B-OSE_Labeled_AE
includes O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
tightness I-OSE_Labeled_AE
, O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
. O

Akathisia B-OSE_Labeled_AE
includes O
akathisia B-OSE_Labeled_AE
and O
restlessness B-OSE_Labeled_AE
. O

Tremor B-OSE_Labeled_AE
includes O
tremor B-OSE_Labeled_AE
and O
parkinsonian B-OSE_Labeled_AE
rest I-OSE_Labeled_AE
tremor I-OSE_Labeled_AE
. O

Dystonia B-OSE_Labeled_AE
includes O
dystonia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
, O
oculogyration B-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
. O
] O

25 O
9 O
Sedation B-OSE_Labeled_AE
11 O
4 O
Akathisia B-OSE_Labeled_AE
9 O
3 O
Tremor B-OSE_Labeled_AE
6 O
3 O
Dizziness B-OSE_Labeled_AE
6 O
5 O
Dystonia B-OSE_Labeled_AE
5 O
1 O
Lethargy B-OSE_Labeled_AE
2 O
1 O
Table O
11 O
lists O
the O
adverse O
reactions O
reported O
in O
2 O
% O
or O
more O
of O
RISPERDAL O
( O
r O
) O
-treated O
adult O
patients O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
in O
two O
3-week O
, O
double-blind O
, O
placebo-controlled O
adjuvant O
therapy O
trials O
. O

Table O
11 O
. O

Adverse O
Reactions O
in O
> O
=2 O
% O
of O
RISPERDAL O
( O
r O
) O
-Treated O
Adult O
Patients O
( O
and O
greater O
than O
placebo O
) O
with O
Bipolar O
Mania O
in O
Double-Blind O
, O
Placebo-Controlled O
Adjunctive O
Therapy O
Trials O
Percentage O
of O
Patients O
Reporting O
Reaction O
System/Organ O
Class O
RISPERDAL O
( O
r O
) O
+ O
Mood O
Stabilizer O
Placebo O
+ O
Mood O
Stabilizer O
Adverse O
Reaction O
( O
N=127 O
) O
( O
N=126 O
) O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Palpitations B-OSE_Labeled_AE
2 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Dyspepsia B-OSE_Labeled_AE
9 O
8 O
Nausea B-OSE_Labeled_AE
6 O
4 O
Diarrhea B-OSE_Labeled_AE
6 O
4 O
Salivary B-OSE_Labeled_AE
hypersecretion I-OSE_Labeled_AE
2 O
0 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
2 O
1 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
2 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Parkinsonism B-OSE_Labeled_AE
[ O
note O
: O
Parkinsonism B-OSE_Labeled_AE
includes O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
and O
bradykinesia B-OSE_Labeled_AE
. O

Akathisia B-OSE_Labeled_AE
includes O
hyperkinesia B-OSE_Labeled_AE
and O
akathisia B-OSE_Labeled_AE
. O
] O

14 O
4 O
Sedation B-OSE_Labeled_AE
9 O
4 O
Akathisia B-OSE_Labeled_AE
8 O
0 O
Dizziness B-OSE_Labeled_AE
7 O
2 O
Tremor B-OSE_Labeled_AE
6 O
2 O
Lethargy B-OSE_Labeled_AE
2 O
1 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
3 O
2 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
5 O
2 O
Cough B-OSE_Labeled_AE
2 O
0 O
Pediatric O
Patients O
with O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
Table O
12 O
lists O
the O
adverse O
reactions O
reported O
in O
5 O
% O
or O
more O
of O
RISPERDAL O
( O
r O
) O
-treated O
pediatric O
patients O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
in O
a O
3-week O
double-blind O
, O
placebo-controlled O
trial O
. O

Table O
12 O
. O

Adverse O
Reactions O
in O
> O
=5 O
% O
of O
RISPERDAL O
( O
r O
) O
-Treated O
Pediatric O
Patients O
( O
and O
greater O
than O
placebo O
) O
with O
Bipolar O
Mania O
in O
Double-Blind O
, O
Placebo-Controlled O
Trials O
Percentage O
of O
Patients O
Reporting O
Reaction O
RISPERDAL O
( O
r O
) O
System/Organ O
Class O
Adverse O
Reaction O
0.5-2.5 O
mg O
per O
day O
( O
N=50 O
) O
3-6 O
mg O
per O
day O
( O
N=61 O
) O
Placebo O
( O
N=58 O
) O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
4 O
7 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
16 O
13 O
5 O
Nausea B-OSE_Labeled_AE
16 O
13 O
7 O
Vomiting B-OSE_Labeled_AE
10 O
10 O
5 O
Diarrhea B-OSE_Labeled_AE
8 O
7 O
2 O
Dyspepsia B-OSE_Labeled_AE
10 O
3 O
2 O
Stomach B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
6 O
0 O
2 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
18 O
30 O
3 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
4 O
7 O
2 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Sedation B-OSE_Labeled_AE
42 O
56 O
19 O
Dizziness B-OSE_Labeled_AE
16 O
13 O
5 O
Parkinsonism B-OSE_Labeled_AE
[ O
note O
: O
Parkinsonism B-OSE_Labeled_AE
includes O
musculoskeletal B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
bradykinesia B-OSE_Labeled_AE
, O
and O
nuchal B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
. O

Dystonia B-OSE_Labeled_AE
includes O
dystonia B-OSE_Labeled_AE
, O
laryngospasm B-OSE_Labeled_AE
, O
and O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
. O

Akathisia B-OSE_Labeled_AE
includes O
restlessness B-OSE_Labeled_AE
and O
akathisia B-OSE_Labeled_AE
. O
] O

6 O
12 O
3 O
Dystonia B-OSE_Labeled_AE
6 O
5 O
0 O
Akathisia B-OSE_Labeled_AE
0 O
8 O
2 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
0 O
8 O
3 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
10 O
3 O
5 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
0 O
7 O
2 O
Commonly-Observed O
Adverse O
Reactions O
in O
Double-Blind O
, O
Placebo-Controlled O
Clinical O
Trials O
- O
Autistic O
Disorder O
Table O
13 O
lists O
the O
adverse O
reactions O
reported O
in O
5 O
% O
or O
more O
of O
RISPERDAL O
( O
r O
) O
-treated O
pediatric O
patients O
treated O
for O
irritability B-Not_AE_Candidate
associated I-Not_AE_Candidate
with I-Not_AE_Candidate
autistic I-Not_AE_Candidate
disorder I-Not_AE_Candidate
in O
two O
8-week O
, O
double-blind O
, O
placebo-controlled O
trials O
and O
one O
6-week O
double-blind O
, O
placebo-controlled O
study O
. O

Table O
13 O
. O

Adverse O
Reactions O
in O
> O
=5 O
% O
of O
RISPERDAL O
( O
r O
) O
-Treated O
Pediatric O
Patients O
( O
and O
greater O
than O
placebo O
) O
Treated O
for O
Irritability O
Associated O
with O
Autistic O
Disorder O
in O
Double-Blind O
, O
Placebo-Controlled O
Trials O
Percentage O
of O
Patients O
Reporting O
Reaction O
System/Organ O
Class O
RISPERDAL O
( O
r O
) O
0.5-4.0 O
mg/day O
Placebo O
Adverse O
Reaction O
( O
N=107 O
) O
( O
N=115 O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Vomiting B-OSE_Labeled_AE
20 O
17 O
Constipation B-OSE_Labeled_AE
17 O
6 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
10 O
4 O
Nausea B-OSE_Labeled_AE
8 O
5 O
Salivary B-OSE_Labeled_AE
hypersecretion I-OSE_Labeled_AE
7 O
1 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
31 O
9 O
Pyrexia B-OSE_Labeled_AE
16 O
13 O
Thirst B-OSE_Labeled_AE
7 O
4 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
19 O
9 O
Rhinitis B-OSE_Labeled_AE
9 O
7 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
8 O
3 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
8 O
2 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
44 O
15 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Sedation B-OSE_Labeled_AE
63 O
15 O
Drooling B-OSE_Labeled_AE
12 O
4 O
Headache B-OSE_Labeled_AE
12 O
10 O
Tremor B-OSE_Labeled_AE
8 O
1 O
Dizziness B-OSE_Labeled_AE
8 O
2 O
Parkinsonism B-OSE_Labeled_AE
[ O
note O
: O
Parkinsonism B-OSE_Labeled_AE
includes O
musculoskeletal B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
and O
muscle B-OSE_Labeled_AE
tightness I-OSE_Labeled_AE
. O
] O

8 O
1 O
Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
Enuresis B-OSE_Labeled_AE
16 O
10 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
17 O
12 O
Rhinorrhea B-OSE_Labeled_AE
12 O
10 O
Nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
10 O
4 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
8 O
5 O
Other O
Adverse O
Reactions O
Observed O
During O
the O
Clinical O
Trial O
Evaluation O
of O
Risperidone O
The O
following O
additional O
adverse O
reactions O
occurred O
across O
all O
placebo-controlled O
, O
active-controlled O
, O
and O
open-label O
studies O
of O
RISPERDAL O
( O
r O
) O
in O
adults O
and O
pediatric O
patients O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
anemia B-OSE_Labeled_AE
, O
granulocytopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
: O
sinus B-OSE_Labeled_AE
bradycardia I-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
, O
atrioventricular B-OSE_Labeled_AE
block I-OSE_Labeled_AE
first I-OSE_Labeled_AE
degree I-OSE_Labeled_AE
, O
bundle B-OSE_Labeled_AE
branch I-OSE_Labeled_AE
block I-OSE_Labeled_AE
left I-OSE_Labeled_AE
, O
bundle B-OSE_Labeled_AE
branch I-OSE_Labeled_AE
block I-OSE_Labeled_AE
right I-OSE_Labeled_AE
, O
atrioventricular B-OSE_Labeled_AE
block I-OSE_Labeled_AE
Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
Disorders I-NonOSE_AE
: O
ear B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
Endocrine B-NonOSE_AE
Disorders I-NonOSE_AE
: O
hyperprolactinemia B-OSE_Labeled_AE
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
ocular B-OSE_Labeled_AE
hyperemia I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
discharge I-OSE_Labeled_AE
, O
conjunctivitis B-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
rolling I-OSE_Labeled_AE
, O
eyelid B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
eyelid B-OSE_Labeled_AE
margin I-OSE_Labeled_AE
crusting I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
eye I-OSE_Labeled_AE
, O
lacrimation B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
photophobia B-OSE_Labeled_AE
, O
glaucoma B-OSE_Labeled_AE
, O
visual B-OSE_Labeled_AE
acuity I-OSE_Labeled_AE
reduced I-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
dysphagia B-OSE_Labeled_AE
, O
fecaloma B-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
lip B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
cheilitis B-OSE_Labeled_AE
, O
aptyalism B-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
: O
edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
, O
thirst B-OSE_Labeled_AE
, O
gait B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
illness I-OSE_Labeled_AE
, O
pitting B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
sluggishness B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
discomfort B-OSE_Labeled_AE
, O
generalized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
coldness I-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
drug B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
: O
pneumonia B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
ear B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
tonsillitis B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
localized B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
, O
onychomycosis B-OSE_Labeled_AE
, O
acarodermatitis B-OSE_Labeled_AE
, O
bronchopneumonia B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
tracheobronchitis B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
chronic I-OSE_Labeled_AE
Investigations B-NonOSE_AE
: O
body B-OSE_Labeled_AE
temperature I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
electrocardiogram B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
eosinophil B-OSE_Labeled_AE
count I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
white B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hemoglobin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
hematocrit B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
body B-OSE_Labeled_AE
temperature I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
transaminases B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
: O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
polydipsia B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
joint B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
joint B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
chest I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
posture B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
muscular B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
rhabdomyolysis B-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
balance B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
unresponsive B-OSE_Labeled_AE
to I-OSE_Labeled_AE
stimuli I-OSE_Labeled_AE
, O
depressed B-OSE_Labeled_AE
level I-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
movement B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
, O
coordination B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
speech B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
neuroleptic B-OSE_Labeled_AE
malignant I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
diabetic B-OSE_Labeled_AE
coma I-OSE_Labeled_AE
, O
head B-OSE_Labeled_AE
titubation I-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
agitation B-OSE_Labeled_AE
, O
blunted B-OSE_Labeled_AE
affect I-OSE_Labeled_AE
, O
confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
, O
middle B-OSE_Labeled_AE
insomnia I-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
sleep B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
listlessness B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
and O
anorgasmia B-OSE_Labeled_AE
Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
: O
enuresis B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
pollakiuria B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
: O
menstruation B-OSE_Labeled_AE
irregular I-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
gynecomastia B-OSE_Labeled_AE
, O
galactorrhea B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
discharge I-OSE_Labeled_AE
, O
menstrual B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
retrograde B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
sexual B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
: O
wheezing B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
aspiration I-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
dysphonia B-OSE_Labeled_AE
, O
productive B-OSE_Labeled_AE
cough I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
rales B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hyperventilation B-OSE_Labeled_AE
, O
nasal B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
erythema B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
lesion I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
maculopapular I-OSE_Labeled_AE
, O
acne B-OSE_Labeled_AE
, O
hyperkeratosis B-OSE_Labeled_AE
, O
seborrheic B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
hypotension B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
Additional O
Adverse O
Reactions O
Reported O
with O
RISPERDAL O
CONSTA O
( O
r O
) O
The O
following O
is O
a O
list O
of O
additional O
adverse O
reactions O
that O
have O
been O
reported O
during O
the O
premarketing O
evaluation O
of O
RISPERDAL O
CONSTA O
( O
r O
) O
, O
regardless O
of O
frequency O
of O
occurrence O
: O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
: O
bradycardia B-OSE_Labeled_AE
Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
Disorders I-NonOSE_AE
: O
vertigo B-OSE_Labeled_AE
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
blepharospasm B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
toothache B-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
: O
pain B-OSE_Labeled_AE
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
: O
lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
subcutaneous B-OSE_Labeled_AE
abscess I-OSE_Labeled_AE
Injury B-NonOSE_AE
and I-NonOSE_AE
Poisoning I-NonOSE_AE
: O
fall B-OSE_Labeled_AE
Investigations B-NonOSE_AE
: O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
gamma B-OSE_Labeled_AE
- I-OSE_Labeled_AE
glutamyltransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
, I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Bone I-NonOSE_AE
Disorders I-NonOSE_AE
: O
buttock B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
convulsion B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
depression B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
eczema B-OSE_Labeled_AE
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
hypertension B-OSE_Labeled_AE
Discontinuations O
Due O
to O
Adverse O
Reactions O
Schizophrenia B-Not_AE_Candidate
- O
Adults O
Approximately O
7 O
% O
( O
39/564 O
) O
of O
RISPERDAL O
( O
r O
) O
-treated O
patients O
in O
double-blind O
, O
placebo-controlled O
trials O
discontinued O
treatment O
due O
to O
an O
adverse O
reaction O
, O
compared O
with O
4 O
% O
( O
10/225 O
) O
who O
were O
receiving O
placebo O
. O

The O
adverse O
reactions O
associated O
with O
discontinuation O
in O
2 O
or O
more O
RISPERDAL O
( O
r O
) O
-treated O
patients O
were O
: O
Table O
14 O
. O

Adverse O
Reactions O
Associated O
With O
Discontinuation O
in O
2 O
or O
More O
RISPERDAL O
( O
r O
) O
-Treated O
Adult O
Patients O
in O
Schizophrenia O
Trials O
RISPERDAL O
( O
r O
) O
Adverse O
Reaction O
2-8 O
mg/day O
( O
N=366 O
) O
> O
8-16 O
mg/day O
( O
N=198 O
) O
Placebo O
( O
N=225 O
) O
Dizziness B-OSE_Labeled_AE
1.4 O
% O
1.0 O
% O
0 O
% O
Nausea B-OSE_Labeled_AE
1.4 O
% O
0 O
% O
0 O
% O
Vomiting B-OSE_Labeled_AE
0.8 O
% O
0 O
% O
0 O
% O
Parkinsonism B-OSE_Labeled_AE
0.8 O
% O
0 O
% O
0 O
% O
Somnolence B-OSE_Labeled_AE
0.8 O
% O
0 O
% O
0 O
% O
Dystonia B-OSE_Labeled_AE
0.5 O
% O
0 O
% O
0 O
% O
Agitation B-OSE_Labeled_AE
0.5 O
% O
0 O
% O
0 O
% O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
0.5 O
% O
0 O
% O
0 O
% O
Orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
0.3 O
% O
0.5 O
% O
0 O
% O
Akathisia B-OSE_Labeled_AE
0.3 O
% O
2.0 O
% O
0 O
% O
Discontinuation O
for O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( O
including O
Parkinsonism B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
and O
tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
) O
was O
1 O
% O
in O
placebo-treated O
patients O
, O
and O
3.4 O
% O
in O
active O
control-treated O
patients O
in O
a O
double-blind O
, O
placebo- O
and O
active-controlled O
trial O
. O

Schizophrenia O
- O
Pediatrics O
Approximately O
7 O
% O
( O
7/106 O
) O
, O
of O
RISPERDAL O
( O
r O
) O
-treated O
patients O
discontinued O
treatment O
due O
to O
an O
adverse O
reaction O
in O
a O
double-blind O
, O
placebo-controlled O
trial O
, O
compared O
with O
4 O
% O
( O
2/54 O
) O
placebo-treated O
patients O
. O

The O
adverse O
reactions O
associated O
with O
discontinuation O
for O
at O
least O
one O
RISPERDAL O
( O
r O
) O
-treated O
patient O
were O
dizziness B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
somnolence B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
sedation B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
lethargy B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
anxiety B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
balance B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
1 O
% O
) O
, O
hypotension B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
palpitation B-OSE_Labeled_AE
( O
1 O
% O
) O
. O

Bipolar O
Mania O
- O
Adults O
In O
double-blind O
, O
placebo-controlled O
trials O
with O
RISPERDAL O
( O
r O
) O
as O
monotherapy O
, O
approximately O
6 O
% O
( O
25/448 O
) O
of O
RISPERDAL O
( O
r O
) O
-treated O
patients O
discontinued O
treatment O
due O
to O
an O
adverse O
event O
, O
compared O
with O
approximately O
5 O
% O
( O
19/424 O
) O
of O
placebo-treated O
patients O
. O

The O
adverse O
reactions O
associated O
with O
discontinuation O
in O
RISPERDAL O
( O
r O
) O
-treated O
patients O
were O
: O
Table O
15 O
. O

Adverse O
Reactions O
Associated O
With O
Discontinuation O
in O
2 O
or O
More O
RISPERDAL O
( O
r O
) O
-Treated O
Adult O
Patients O
in O
Bipolar O
Mania O
Clinical O
Trials O
Adverse O
Reaction O
RISPERDAL O
( O
r O
) O
1-6 O
mg/day O
( O
N=448 O
) O
Placebo O
( O
N=424 O
) O
Parkinsonism B-OSE_Labeled_AE
0.4 O
% O
0 O
% O
Lethargy B-OSE_Labeled_AE
0.2 O
% O
0 O
% O
Dizziness B-OSE_Labeled_AE
0.2 O
% O
0 O
% O
Alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
0.2 O
% O
0.2 O
% O
Aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
0.2 O
% O
0.2 O
% O
Bipolar O
Mania O
- O
Pediatrics O
In O
a O
double-blind O
, O
placebo-controlled O
trial O
12 O
% O
( O
13/111 O
) O
of O
RISPERDAL O
( O
r O
) O
-treated O
patients O
discontinued O
due O
to O
an O
adverse O
reaction O
, O
compared O
with O
7 O
% O
( O
4/58 O
) O
of O
placebo-treated O
patients O
. O

The O
adverse O
reactions O
associated O
with O
discontinuation O
in O
more O
than O
one O
RISPERDAL O
( O
r O
) O
-treated O
pediatric O
patient O
were O
nausea B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
somnolence B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
sedation B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
and O
vomiting B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

Autistic O
Disorder O
- O
Pediatrics O
In O
the O
two O
8-week O
, O
placebo-controlled O
trials O
in O
pediatric O
patients O
treated O
for O
irritability B-Not_AE_Candidate
associated I-Not_AE_Candidate
with I-Not_AE_Candidate
autistic I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
n=156 O
) O
, O
one O
RISPERDAL O
( O
r O
) O
-treated O
patient O
discontinued O
due O
to O
an O
adverse O
reaction O
( O
Parkinsonism B-OSE_Labeled_AE
) O
, O
and O
one O
placebo-treated O
patient O
discontinued O
due O
to O
an O
adverse O
event O
. O

Dose O
Dependency O
of O
Adverse O
Reactions O
in O
Clinical O
Trials O
Extrapyramidal O
Symptoms O
Data O
from O
two O
fixed-dose O
trials O
in O
adults O
with O
schizophrenia B-Not_AE_Candidate
provided O
evidence O
of O
dose-relatedness O
for O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
associated O
with O
RISPERDAL O
( O
r O
) O
treatment O
. O

Two O
methods O
were O
used O
to O
measure O
extrapyramidal B-NonOSE_AE
symptoms I-NonOSE_AE
( I-NonOSE_AE
EPS I-NonOSE_AE
) O
in O
an O
8-week O
trial O
comparing O
4 O
fixed O
doses O
of O
RISPERDAL O
( O
r O
) O
( O
2 O
, O
6 O
, O
10 O
, O
and O
16 O
mg/day O
) O
, O
including O
( O
1 O
) O
a O
Parkinsonism B-NonOSE_AE
score O
( O
mean O
change O
from O
baseline O
) O
from O
the O
Extrapyramidal B-NonOSE_AE
Symptom I-NonOSE_AE
Rating O
Scale O
, O
and O
( O
2 O
) O
incidence O
of O
spontaneous O
complaints O
of O
EPS B-NonOSE_AE
: O
Table O
16 O
. O

Dose O
Groups O
Placebo O
RISPERDAL O
( O
r O
) O
2 O
mg O
RISPERDAL O
( O
r O
) O
6 O
mg O
RISPERDAL O
( O
r O
) O
10 O
mg O
RISPERDAL O
( O
r O
) O
16 O
mg O
Parkinsonism B-OSE_Labeled_AE
1.2 O
0.9 O
1.8 O
2.4 O
2.6 O
EPS B-OSE_Labeled_AE
Incidence O
13 O
% O
17 O
% O
21 O
% O
21 O
% O
35 O
% O
Similar O
methods O
were O
used O
to O
measure O
extrapyramidal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
EPS O
) O
in O
an O
8-week O
trial O
comparing O
5 O
fixed O
doses O
of O
RISPERDAL O
( O
r O
) O
( O
1 O
, O
4 O
, O
8 O
, O
12 O
, O
and O
16 O
mg/day O
) O
: O
Table O
17 O
. O

Dose O
Groups O
RISPERDAL O
( O
r O
) O
1 O
mg O
RISPERDAL O
( O
r O
) O
4 O
mg O
RISPERDAL O
( O
r O
) O
8 O
mg O
RISPERDAL O
( O
r O
) O
12 O
mg O
RISPERDAL O
( O
r O
) O
16 O
mg O
Parkinsonism B-OSE_Labeled_AE
0.6 O
1.7 O
2.4 O
2.9 O
4.1 O
EPS B-OSE_Labeled_AE
Incidence O
7 O
% O
12 O
% O
17 O
% O
18 O
% O
20 O
% O
Dystonia O
Class O
Effect O
: O
Symptoms O
of O
dystonia B-OSE_Labeled_AE
, O
prolonged B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
contractions I-OSE_Labeled_AE
of I-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
groups I-OSE_Labeled_AE
, O
may O
occur O
in O
susceptible O
individuals O
during O
the O
first O
few O
days O
of O
treatment O
. O

Dystonic B-NonOSE_AE
symptoms I-NonOSE_AE
include O
: O
spasm B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
neck I-NonOSE_AE
muscles I-NonOSE_AE
, O
sometimes O
progressing O
to O
tightness B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
throat I-NonOSE_AE
, O
swallowing B-NonOSE_AE
difficulty I-NonOSE_AE
, O
difficulty B-NonOSE_AE
breathing I-NonOSE_AE
, O
and/or O
protrusion B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
tongue I-NonOSE_AE
. O

While O
these O
symptoms O
can O
occur O
at O
low O
doses O
, O
they O
occur O
more O
frequently O
and O
with O
greater O
severity O
with O
high O
potency O
and O
at O
higher O
doses O
of O
first O
generation O
antipsychotic O
drugs O
. O

An O
elevated O
risk O
of O
acute B-NonOSE_AE
dystonia I-NonOSE_AE
is O
observed O
in O
males O
and O
younger O
age O
groups O
. O

Other O
Adverse O
Reactions O
Adverse O
event O
data O
elicited O
by O
a O
checklist O
for O
side O
effects O
from O
a O
large O
study O
comparing O
5 O
fixed O
doses O
of O
RISPERDAL O
( O
r O
) O
( O
1 O
, O
4 O
, O
8 O
, O
12 O
, O
and O
16 O
mg/day O
) O
were O
explored O
for O
dose-relatedness O
of O
adverse O
events O
. O

A O
Cochran-Armitage O
Test O
for O
trend O
in O
these O
data O
revealed O
a O
positive O
trend O
( O
p O
< O
0.05 O
) O
for O
the O
following O
adverse O
reactions O
: O
somnolence B-OSE_Labeled_AE
, O
vision B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
palpitations B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
sexual B-OSE_Labeled_AE
function I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
and O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
. O

Changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Body I-OSE_Labeled_AE
Weight I-OSE_Labeled_AE
Weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
was O
observed O
in O
short-term O
, O
controlled O
trials O
and O
longer-term O
uncontrolled O
studies O
in O
adult O
and O
pediatric O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
, O
Adverse O
Reactions O
( O
6 O
) O
, O
and O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

Changes O
in O
ECG O
Parameters O
Between-group O
comparisons O
for O
pooled O
placebo-controlled O
trials O
in O
adults O
revealed O
no O
statistically O
significant O
differences O
between O
risperidone O
and O
placebo O
in O
mean O
changes B-NonOSE_AE
from I-NonOSE_AE
baseline I-NonOSE_AE
in I-NonOSE_AE
ECG I-NonOSE_AE
parameters I-NonOSE_AE
, O
including O
QT O
, O
QTc O
, O
and O
PR O
intervals O
, O
and O
heart O
rate O
. O

When O
all O
RISPERDAL O
( O
r O
) O
doses O
were O
pooled O
from O
randomized O
controlled O
trials O
in O
several O
indications O
, O
there O
was O
a O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
of O
1 O
beat O
per O
minute O
compared O
to O
no O
change O
for O
placebo O
patients O
. O

In O
short-term O
schizophrenia B-Not_AE_Candidate
trials O
, O
higher O
doses O
of O
risperidone O
( O
8-16 O
mg/day O
) O
were O
associated O
with O
a O
higher O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
compared O
to O
placebo O
( O
4-6 O
beats O
per O
minute O
) O
. O

In O
pooled O
placebo-controlled O
acute B-Not_AE_Candidate
mania I-Not_AE_Candidate
trials O
in O
adults O
, O
there O
were O
small O
decreases B-NonOSE_AE
in I-NonOSE_AE
mean I-NonOSE_AE
heart I-NonOSE_AE
rate I-NonOSE_AE
, O
similar O
among O
all O
treatment O
groups O
. O

In O
the O
two O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
autistic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
aged O
5 O
- O
16 O
years O
) O
mean O
changes O
in O
heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
were O
an O
increase I-OSE_Labeled_AE
of O
8.4 O
beats O
per O
minute O
in O
the O
RISPERDAL O
( O
r O
) O
groups O
and O
6.5 O
beats O
per O
minute O
in O
the O
placebo O
group O
. O

There O
were O
no O
other O
notable O
ECG B-NonOSE_AE
changes I-NonOSE_AE
. O

In O
a O
placebo-controlled O
acute B-Not_AE_Candidate
mania I-Not_AE_Candidate
trial O
in O
children O
and O
adolescents O
( O
aged O
10 O
- O
17 O
years O
) O
, O
there O
were O
no O
significant O
changes B-NonOSE_AE
in I-NonOSE_AE
ECG I-NonOSE_AE
parameters I-NonOSE_AE
, O
other O
than O
the O
effect O
of O
RISPERDAL O
( O
r O
) O
to O
transiently O
increase B-OSE_Labeled_AE
pulse I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( O
< O
6 O
beats O
per O
minute O
) O
. O

In O
two O
controlled O
schizophrenia B-Not_AE_Candidate
trials O
in O
adolescents O
( O
aged O
13 O
- O
17 O
years O
) O
, O
there O
were O
no O
clinically O
meaningful O
changes B-NonOSE_AE
in I-NonOSE_AE
ECG I-NonOSE_AE
parameters I-NonOSE_AE
including O
corrected O
QT O
intervals O
between O
treatment O
groups O
or O
within O
treatment O
groups O
over O
time O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
risperidone O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

These O
adverse O
reactions O
include O
: O
alopecia B-OSE_Labeled_AE
, O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
cardiopulmonary B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
diabetic B-OSE_Labeled_AE
ketoacidosis I-OSE_Labeled_AE
in O
patients O
with O
impaired B-Not_AE_Candidate
glucose I-Not_AE_Candidate
metabolism I-Not_AE_Candidate
, O
dysgeusia B-OSE_Labeled_AE
, O
hypoglycemia B-OSE_Labeled_AE
, O
hypothermia B-OSE_Labeled_AE
, O
ileus B-OSE_Labeled_AE
, O
inappropriate B-OSE_Labeled_AE
antidiuretic I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
mania B-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
pituitary B-OSE_Labeled_AE
adenoma I-OSE_Labeled_AE
, O
precocious B-OSE_Labeled_AE
puberty I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
, O
sleep B-OSE_Labeled_AE
apnea I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
and O
water B-OSE_Labeled_AE
intoxication I-OSE_Labeled_AE
. O

